Kinesin gene variability may affect tau phosphorylation in early Alzheimer's disease

International Journal of Molecular Medicine

Volumn 20, Issue 2, 2007, Pages 233-239

  Andersson, Malin E ^a   Sjölander, Annica ^a   Andreasen, Niels ^b   Minthon, Lennart ^c,d   Hansson, Oskar ^c,d   Bogdanovic, Nenad ^b   Jern, Christina ^a   Jood, Katarina ^a   Wallin, Anders ^a   Blennow, Kaj ^a   Zetterberg, Henrik ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer's disease; Apolipoprotein E; Axonal transport; Biomarkers; Kinesin; Polymorphism

Indexed keywords

APOLIPOPROTEIN E; KINESIN LIGHT CHAIN PROTEINS; KINESIN LIGHT-CHAIN PROTEINS; MICROTUBULE ASSOCIATED PROTEIN; PROTEIN KINASE; TAU PROTEIN; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; CASE CONTROL STUDY; COMPARATIVE STUDY; DISEASE COURSE; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEINS E; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; GENE FREQUENCY; HUMANS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; PHOSPHORYLATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN KINASES; TAU PROTEINS; VARIATION (GENETICS);

EID: 34347242354     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.20.2.233     Document Type: Article

References (40)

1. Blennow K, de Leon MJ and Zetterberg H: Alzheimer's disease. Lancet 368: 387-403, 2006.
2. Hardy J and Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356, 2002.
3. Terry RD: The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis. J Neuropathol Exp Neurol 55: 1023-1025, 1996.
4. Stokin GB and Goldstein LS: Axonal transport and Alzheimer's disease. Annu Rev Biochem 75: 607-627, 2006.
5. Inomata H, Nakamura Y, Hayakawa A, Takata H, Suzuki T, Miyazawa K and Kitamura N: A scaffold protein JIP-1b enhances amyloid precursor protein phosphorylation by JNK and its association with kinesin light chain 1. J Biol Chem 278: 22946-22955, 2003.
6. Kamal A, Stokin GB, Yang Z, Xia CH and Goldstein LS: Axonal transport of amyloid precursor protein is mediated by direct binding to the kinesin light chain subunit of kinesin-I. Neuron 28: 449-459, 2000.
7. Matsuda S, Matsuda Y and D'Adamio L: Amyloid beta protein precursor (AbetaPP), but not AbetaPP-like protein 2, is bridged to the kinesin light chain by the scaffold protein JNK-interacting protein 1. J Biol Chem 278: 38601-38606, 2003.
8. Amaratunga A, Leeman SE, Kosik KS and Fine RE: Inhibition of kinesin synthesis in vivo inhibits the rapid transport of representative proteins for three transport vesicle classes into the axon. J Neurochem 64: 2374-2376, 1995.
9. Kaether C, Skehel P and Dotti CG: Axonal membrane proteins are transported in distinct carriers: a two-color video microscopy study in cultured hippocampal neurons. Mol Biol Cell 11: 1213-1224, 2000.
10. Kamal A, Almenar-Queralt A, LeBlanc JF, Roberts EA and Goldstein LS: Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP. Nature 414: 643-648, 2001.
11. Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL, Raman R, Davies P, Masliah E, Williams DS and Goldstein LS: Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 307: 1282-1288, 2005.
12. Gunawardena S and Goldstein LS: Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in Drosophila. Neuron 32: 389-401, 2001.
13. Chen XH, Siman R, Iwata A, Meaney DF, Trojanowski JQ and Smith DH: Long-term accumulation of amyloid-beta, beta-secretase, presenilin-1, and caspase-3 in damaged axons following brain trauma. Am J Pathol 165: 357-371, 2004.
14. Kawarabayashi T, Shoji M, Yamaguchi H, Tanaka M, Harigaya Y, Ishiguro K and Hirai S: Amyloid beta protein precursor accumulates in swollen neurites throughout rat brain with aging. Neurosci Lett 153: 73-76, 1993.
15. Smith DH, Chen XH, Iwata A and Graham DI: Amyloid beta accumulation in axons after traumatic brain injury in humans. J Neurosurg 98: 1072-1077, 2003.
16. Dhaenens CM, Van Brussel E, Schraen-Maschke S, Pasquier F, Delacourte A and Sablonniere B: Association study of three polymorphisms of kinesin light-chain 1 gene with Alzheimer's disease. Neurosci Lett 368: 290-292, 2004.
17. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K and Minthon L: Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5: 228-234, 2006.
18. Jood K, Ladenvall C, Rosengren A, Blomstrand C and Jern C: Family history in ischemic stroke before 70 years of age: the Sahlgrenska Academy Study on Ischemic Stroke. Stroke 36: 1383-1387, 2005.
19. McKhann G, Drachman D, Folstein M, Katzman R, Price D and Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944, 1984.
20. Folstein MF, Folstein SE and McHugh PR: 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198, 1975.
21. Alafuzoff I, Iqbal K, Friden H, Adolfsson R and Winblad B: Histopathological criteria for progressive dementia disorders: clinical-pathological correlation and classification by multivariate data analysis. Acta Neuropathol 74: 209-225, 1987.
22. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG and Kokmen E: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56: 303-308, 1999.
23. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. Third edition, revised edition. American Psychiatric Association, Arlington, VA, 1987.
24. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A and Hofman A: Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43: 250-260, 1993.
25. McKeith IG, Perry EK and Perry RH: Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies. Neurology 53: 902-905, 1999.
26. Brun A, Englund E, Gustafson L, Passant U, Mann D, Neary D and Snowden J: Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. J Neurol Neurosurg Psychiatry 57: 416-418, 1994.
27. Wilhelmsen L, Johansson S, Rosengren A, Wallin I, Dotevall A and Lappas G: Risk factors for cardiovascular disease during the period 1985-1995 in Goteborg, Sweden. The GOT-MONICA Project. J Intern Med 242: 199-211, 1997.
28. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, Vanderstichele H, Vanmechelen E and Blennow K: Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 56: 673-680, 1999.
29. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J and Vanmechelen E: Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 26: 231-245, 1995.
30. Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, Minthon L, Wallin A, Blennow K and Vanmechelen E: Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid 7: 245-258, 2000.
31. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjogren M, Andreasen N and Blennow K: Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 285: 49-52, 2000.
32. Eyre TA, Ducluzeau F, Sneddon TP, Povey S, Bruford EA and Lush MJ: The HUGO Gene Nomenclature Database, 2006 updates. Nucleic Acids Res 34: D319-D321, 2006.
33. Blennow K, Ricksten A, Prince JA, Brookes AJ, Emahazion T, Wasslavik C, Bogdanovic N, Andreasen N, Batsman S, Marcusson J, Nagga K, Wallin A, Regland B, Olofsson H, Hesse C, Davidsson P, Minthon L, Jansson A, Palmqvist L and Rymo L: No association between the alpha2-macroglobulin (A2M) deletion and Alzheimer's disease, and no change in A2M mRNA, protein, or protein expression. J Neural Transm 107: 1065-1079, 2000.
34. Bertram L and Tanzi RE: Alzheimer's disease: one disorder, too many genes? Hum Mol Genet 13: R135-R141, 2004.
35. Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P and Gauthier S: Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 342: 697-699, 1993.
36. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS and Roses AD: Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 90: 1977-1981, 1993.
37. McCart AE, Mahony D and Rothnagel JA: Alternatively spliced products of the human kinesin light chain 1 (KNS2) gene. Traffic 4: 576-580, 2003.
38. Morfini G, Szebenyi G, Elluru R, Ratner N and Brady ST: Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility. EMBO J 21: 281-293, 2002.
39. Woodgett JR: Regulation and functions of the glycogen synthase kinase-3 subfamily. Semin Cancer Biol 5: 269-275, 1994.
40. Pei JJ, Tanaka T, Tung YC, Braak E, Iqbal K and Grundke-Iqbal I: Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J Neuropathol Exp Neurol 56: 70-78, 1997.